Jason Mallo, DO

Clinical Update

How to Diagnose Borderline Personality Disorder

January 1, 2025

C. Jason Mallo, DO. Division Medical Director, Maine Medical Center Department of Psychiatry, Adult Outpatient Psychiatry. Assistant Clinical Professor, Tufts University School of Medicine.

Dr. Mallo has no financial relationships with companies related to this material.

We show you how to ask about borderline criteria and how to convey the diagnosis to the patient.

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

October 18, 2024

Jason Mallo, DO and Greg Malzberg, MD

In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.

Alpha-2 Agonists Review: Clonidine (Kapvay) and Guanfacine (Intuniv), Non-Stimulant ADHD Medications

October 6, 2024

Jason Mallo, DO and Greg Malzberg, MD

In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.

CARLAT WEBINAR

How to Diagnose Borderline Personality Disorder

January 22, 2024

Jason Mallo, DO

0.50 CME Credits. You do not need to be an expert in borderline personality to help your patients. Dr. Mallo will introduce tactics that can be applied in different treatment settings.

Hypothyroidism and Depression: Just How Related Are They?

June 1, 2022

Jason Mallo, DO

C. Jason Mallo, DO. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A landmark study puts a spotlight on whether patients can successfully taper off their antidepressant without relapsing.

Atomoxetine: Myths and Truths

September 10, 2021

Jason Mallo, DO

Jason Mallo, DO. Attending psychiatrist, Maine Medical Center, Portland, ME. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).

A Closer Look at Alpha-2 Agonists for ADHD

March 11, 2021

Jason Mallo, DO

C. Jason Mallo, DO. Attending Psychiatrist, Maine Medical Center, Portland, Maine. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Now that guanfacine ER (Intuniv) and clonidine ER (Kapvay) have gone generic, we review the 40-years of research that earned them FDA approval in ADHD. Along the way we’ll consider their off-label use in anxiety, addiction, insomnia, and self-harm. Plus: When to use the ER, the instant release, or the oft-forgotten transdermal patch.

E-Cigarettes vs Nicotine Replacement for Smoking Cessation

June 10, 2020

Jason Mallo, DO

Jason Mallo, DO. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Quitting smoking remains extremely difficult. This multicenter randomized controlled trial evaluates the efficacy of using e-cigarettes compared to nicotine replacement among adults (average age 41) seeking help to quit smoking.

New Hope: CBT for Internet and Computer Game Addiction

February 11, 2020

Jason Mallo, DO

Jason Mallo, DO Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Internet and computer game addictions represent difficult-to-define and difficult-to-treat conditions that are increasing in prevalence. To provide some guidance on treatment options, investigators tested short-term cognitive behavioral therapy in a randomized, controlled trial.

Polypharmacy in Schizophrenia

February 10, 2020

Jason Mallo, DO

Jason Mallo, DO. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Polypharmacy is often practiced in schizophrenia, but you have to look hard to find any evidence that it helps. These two large-scale studies lend some empiric support to the practice, but also give us insights into how it could go wrong.